Download Jørn Herrstedt, MD, DMSci

Jørn Herrstedt, MD, DMSci
Jørn Herrstedt is Clinical Professor at the University of Southern Denmark and Senior
Consultant at the Department of Oncology, Odense University Hospital (OUH), Denmark.
He is Head of Research in Oncology and of the Clinical Research Unit at the Department
of Oncology, Odense University Hospital..
Dr. Herrstedt obtained his MD at the University of Copenhagen in 1983. He is a board
certified specialist in Internal Medicine (1997) and trained in Medical Oncology and
defended his doctorial thesis: “Chemotherapy-induced nausea and vomiting with special
emphasis on metopimazine” at the University of Copenhagen in 1998.
His primary research interests include supportive care, gynaecological oncology and
cancer in the elderly and he has been PI on several international trials.
He has 100+ publications in journals such as New England Journal of Medicine, British
Medical Journal, Lancet Oncology, Nature Clinical Practice in Oncology, Journal of
Oncology and Annals of Oncology.
Dr Herrstedt has been a member of 10+ international Scientific Committees (MASCC,
ESMO, ECCO) and given 60+ international invited oral presentations. .
Dr. Herrstedt was Board member (1999-2011) and President (2008-2010) of the
Multinational Association of Supportive Care in Cancer and is currently Board member of
the Nordic Society of Gynecologic Oncology (NSGO) and chair of the ESMO Faculty on
Supportive and Palliative Care (2012-2014). He is associated Editor-in-Chief for
Supportive Care in Cancer and Advisory Board member for Acta Oncologica.
Selected publications 2008-2012
J Herrstedt.
Antiemetics 2007: An update and the MASCC guidelines applied in clinical practice.
Nature Clin Pract Oncol 2008;5:32-43.
E Ellebæk , J Herrstedt.
Optimizing antiemetic therapy in multiple-day and multiple cycles of chemotherapy.
Current Opin Support Pall Care 2008;2:28-34.
J Herrstedt, F Roila on behalf of the ESMO Guidelines Working Group.
Chemotherapy-induced nausea and vomiting: ESMO clinical recommendations for
prophylaxis. Ann Oncol 2008;19(suppl 2):ii110-112.
J Jakobsen, J Herrstedt.
Prevention of chemotherapy-induced nausea and vomiting in elderly cancer patients.
Crit Rev Oncol/Hematol 2009; 71;214-221.
SM Grunberg, J Rolski, J Strausz, Z Aziz, S Lane, MW Russo, PW, M Guckert, O Wright,
Herrstedt.
Efficacy and Safety of the Neurokinin-1 Receptor Antagonist Casopitant for the Prevention
of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic
Chemotherapy Over Multiple Cycles.
Lancet Oncology 2009;10:549-558.
C Ruhlmann, J Herrstedt.
Casopitant: a novel NK1-receptor antagonist in the prevention of chemotherapy-induced
nausea and vomiting.
Therapeutics and Clinical Risk Management 2009;5:375-384.
J Herrstedt, W Apornwirat, A Shaharyar, Z Aziz, F Roila, S Van Belle, MW Russo, J
Levin, S Ranganathan, M Guckert, SM Grunberg.
Phase III trial of Casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of
chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic
chemotherapy.
J Clin Oncol 2009;27:5363-5369.
L Adamsen, M Quist, C Andersen, T Møller, J Herrstedt, D Kronborg, MT Baadsgaard, K
Vistisen, J Midtgaard, B Christiansen, M Stage, M Kronborg, M Rørth.
Effect of a multimodal high-intensity exercise intervention in cancer patients undergoing
chemotherapy: randomized controlled trial.
BMJ 2009;339:b3410.
Ruhlmann C, Herrstedt J.
Palonosetron hydrochloride for the prevention of chemotherapy-induced nausea and
vomiting.
Expert Rev Anticancer Ther 2010;10:137-148.
Du Bois A, Herrstedt J, Hardy-Bessard A-C, Müller H-H, Harter P, Kristensen G, Joly F et
al.
Addition of
gemcitabine as third drug to carboplatin-paclitaxel in firstline treatment of epithelial
ovarian cancer. A prospectively randomized Gynecologic Cancer Intergroup (GCIG)
Intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer
Study Group (AGO-OVAR), the Groupe d’Investigateurs Nationaux pour l’Etude des
Cancers Ovariens (GINECO), and the Nordic Society of Gynecologic Oncology
(NSGO).
J Clin Oncol 2010;28:4162-4169.
Jørgensen TL, Hallas J, Land LH, Herrstedt J.
Comorbidity and polypharmacy in elderly cancer patients: The significance on treatment
outcome and tolerance.
J Geriatric Oncol 2010;1:87-102.
Roila F, Herrstedt J, Aapro MS et al.
Guideline update for MASCC and ESMO in the prevention of chemotherapy- and
radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference.
Ann Oncol 2010;21(suppl 5):v232-v243.
Herrstedt J, Rapoport B, Warr D, Roila F, Bria E, Rittenberg C, Hesketh PJ. Acute
emesis: moderately emetogenic chemotherapy.
Support Care Cancer 2011;19(suppl 1):S15-23.
Ruhlmann C, Herrstedt J
Safety evaluation of of aprepitant for the prevention of CINV.
Expert Opin Drug Safety 2011; 10:449-462.
Bergmann TK, Gréen H, Brasch-Andersen C, Mirza MR, Herrstedt J, Hølund B, du Bois
A, Damkier P, Vach W, Brosen K, Peterson C.
Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and
survival in patients with ovarian cancer.
Eur J Clin Pharmacol 2011;67:693-700.
Grunberg S, Chua D, Maru A, Dinis J, DeVandry S, Boice JA, Hardwick JS, Beckford E,
Taylor A, Carides A, Roila F, Herrstedt J.
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and
vomiting associated with cisplatin therapy: randomized, double-blind study protocol-EASE.
J Clin Oncol 2011;29:14951501.
Jørgensen TL, Herrstedt J, Friis S, Hallas J.
Polypharmacy and drug use in elderly Danish cancer patients during 1996 to 2006.
J Geriatric Oncol 2012;3:33-40.
Ruhlmann C, Herrstedt J.
Fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting.
Expert Rev Anticancer Ther 2012;12:139-150.
Jørgensen TL, Hallas J, Friis S, Herrstedt J
Comorbidity in elderly cancer patients in relation to overall and cancer specific mortality.
Br J Cancer 2012;106:1353-1360.
Jørgensen TL, Teiblum S, Paludan M, Poulsen LØ, Jørgensen AYS, Bruun KS, Hallas J,
Herrstedt J.
Significance of age and comorbidity on treatment modality, treatment adherence and
prognosis in elderly ovarian cancer patients.
Gynecol Oncol 2012, July 16. EPUB ahead of print.